References
- Coller BS. Historical perspective and future directions in platelet research: platelet history and future directions. Journal of Thrombosis and Haemostasis 2011;9:374–395. doi:https://doi.org/10.1111/j.1538-7836.2011.04356.x.
- Davies MJ, Thomas AC, Knapman PA, Hangartner JR. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73(3):418–427. doi:https://doi.org/10.1161/01.CIR.73.3.418.
- Storey RF, Sanderson HM, White AE, May JA, Cameron KE, Heptinstall S. The central role of the P2T receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. British Journal of Haematology 2000;110(4):925–934. doi:https://doi.org/10.1046/j.1365-2141.2000.02208.x.
- Cayla G, Silvain J, Collet J-P, Montalescot G. Updates and current recommendations for the management of patients with Non–ST-Elevation acute coronary syndromes: what it means for clinical practice. The American Journal of Cardiology 2015;115(5):10A–22A. doi:https://doi.org/10.1016/j.amjcard.2015.01.003.
- Rodriguez F, Mahaffey KW. Management of patients with NSTE-ACS. Journal of the American College of Cardiology 2016;68(3):313–321. doi:https://doi.org/10.1016/j.jacc.2016.03.599.
- Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction. Journal of the American College of Cardiology 2016;67(10):1235–1250. doi:https://doi.org/10.1016/j.jacc.2015.10.005.
- Born GVR, Haslam RJ, Goldman M, Lowe RD. Comparative effectiveness of adenosine analogues as inhibitors of blood-platelet aggregation and as vasodilators in man. Nature 1965;205(4972):678–680. doi:https://doi.org/10.1038/205678a0.
- Cattaneo M, Cerletti C, Harrison P, Hayward CPM, Kenny D, Nugent D, Nurden P, Rao AK, Schmaier AH, Watson SP, et al. Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. J Thromb Haemost 2013;11(6):1183–1189. doi:https://doi.org/10.1111/jth.12231.
- Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin : enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96(5):1488–1494. doi:https://doi.org/10.1161/01.CIR.96.5.1488.
- Monkhouse FC, Drechsler K, Weber G, Fidlar E. Relation between heparin and thrombin inactivation. American Journal of Physiology-Legacy Content 1951;165(1):195–204. doi:https://doi.org/10.1152/ajplegacy.1951.165.1.195.
- Harmon JT, Jamieson GA. Platelet activation by ?-Thrombin is a receptor-mediated event. Ann NY Acad Sci 1986;485(1Bioregulatory):387–395. doi:https://doi.org/10.1111/j.1749-6632.1986.tb34599.x.
- Hilpert K, Ackermann J, Banner DW, Gast A, Gubernator K, Hadvary P, Labler L, Mueller K, Schmid G, Tschopp TB, et al. Design and synthesis of potent and highly selective thrombin inhibitors. J Med Chem 1994;37(23):3889–3901. doi:https://doi.org/10.1021/jm00049a008.
- Hijikata-Okunomiya A, Okamoto S, Wanaka K. Effect of a synthetic thrombin-inhibitor MD805 on the reaction between thrombin and plasma antithrombin-III. Thrombosis Res 1990;59(6):967–977. doi:https://doi.org/10.1016/0049-3848(90)90120-2.
- Pittens CACM, Bouman HJ, Van Werkum JW, Ten Berg JM, Hackeng CM. Comparison between hirudin and citrate in monitoring the inhibitory effects of P2Y12 receptor antagonists with different platelet function tests. Journal of Thrombosis and Haemostasis 2009;7(11):1929–1932. doi:https://doi.org/10.1111/j.1538-7836.2009.03585.x.
- Jones S, Evans RJ, Mahaut-Smith MP. Extracellular Ca2+ modulates ADP-evoked aggregation through altered agonist degradation: implications for conditions used to study P2Y receptor activation: role of ectonucleotidases in Ca2+-dependent platelet aggregation. British Journal of Haematology 2011;153(1):83–91. doi:https://doi.org/10.1111/j.1365-2141.2010.08499.x.
- Jiang L, Xu C, Yu S, Liu P, Luo D, Zhou Q, Gao C, Hu H. A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation. J Thromb Haemost 2013;11(5):930–940. doi:https://doi.org/10.1111/jth.12168.
- Rand ML, Perry DW, Packham MA, Gemmell CH, Yeo EL, Kinlough-Rathbone RL. Conditions influencing release of granule contents from human platelets in citrated plasma induced by ADP or the thrombin receptor activating peptide SFLLRN: direct measurement of percent release of beta-thromboglobulin and assessment by flow cytometry of P-selectin expression. Am J Hematol 1996;52(4):288–294. doi:https://doi.org/10.1002/(SICI)1096-8652(199608)52:4<288::AID-AJH8>3.0.CO;2-O.
- Kereiakes DJ, Lorenz T, Young JJ, Kukielka G, Mueller M, Nanniazzi-Alaimo L, Phillips D. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban. J Thromb Thrombolysis 2001;12(2):123–127. doi:https://doi.org/10.1023/a:1012991303381.
- Marciniak SJ, Jordan RE, Mascelli MA. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban. Thromb Haemost 2001;85(3):539–543. doi:https://doi.org/10.1055/s-0037-1615618.
- Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107(23):2908–2913. doi:https://doi.org/10.1161/01.CIR.0000072771.11429.83.
- Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European Heart Journal 2006;27(9):1038–1047. doi:https://doi.org/10.1093/eurheartj/ehi754.
- Asai F, Jakubowski JA, Naganuma H, Brandt JT, Matsushima N, Hirota T, Freestone S, Winters KJ. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans. Platelets 2006;17(4):209–217. doi:https://doi.org/10.1080/09537100600565551.
- Mani H, Hellis M, Lindhoff-Last E. Platelet function testing in hirudin and BAPA anticoagulated blood. Clinical Chemistry and Laboratory Medicine 2011;49(3). doi:https://doi.org/10.1515/CCLM.2011.074.
- Labarthe B, Théroux P, Angioï M, Ghitescu M. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. Journal of the American College of Cardiology 2005;46(4):638–645. doi:https://doi.org/10.1016/j.jacc.2005.02.092.
- Frelinger AL, Jakubowski JA, Li Y, Barnard MR, Linden MD, Tarnow I, Fox ML, Sugidachi A, Winters KJ, Furman MI, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. Journal of Thrombosis and Haemostasis 2008;6(2):359–365. doi:https://doi.org/10.1111/j.1538-7836.2007.02838.x.
- Bouman HJ, Van Werkum JW, Hackeng CM, Verheugt FWA, Ten Berg JM. The importance of anticoagulant agents in measuring platelet aggregation in patients treated with clopidogrel and aspirin. J Thromb Haemost 2008;6(6):1040–1042. doi:https://doi.org/10.1111/j.1538-7836.2008.02971.x.
- Peters RJG, Mehta SR, Fox KAA, Zhao F, Lewis BS, Kopecky SL, Diaz R, Commerford PJ, Valentin V, Yusuf S. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the clopidogrel in unstable angina to prevent recurrent events (CURE) study. Circulation 2003;108(14):1682–1687. doi:https://doi.org/10.1161/01.CIR.0000091201.39590.CB.
- Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH. Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 Trial. Circulation 2005;111(25):3366–3373. doi:https://doi.org/10.1161/CIRCULATIONAHA.104.502815.
- James S, Åkerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, et al. Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. American Heart Journal 2009;157(4):599–605. doi:https://doi.org/10.1016/j.ahj.2009.01.003.
- Angiolillo DJ, Welsh RC, Trenk D, Neumann F-J, Conley PB, McClure MW, Stephens G, Kochman J, Jennings LK, Gurbel PA, et al. Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) trial. Circulation: Cardiovascular Interventions 2012;5(3):347–356. doi:https://doi.org/10.1161/CIRCINTERVENTIONS.111.965608.
- Caroff E, Hubler F, Meyer E, Renneberg D, Gnerre C, Treiber A, Rey M, Hess P, Steiner B, Hilpert K, et al. 4-((R)-2-{[6-((S)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic acid butyl ester (ACT-246475) and Its Prodrug (ACT-281959), a novel P2Y12 receptor antagonist with a wider therapeutic window in the rat than clopidogrel. J Med Chem 2015;58(23):9133–9153. doi:https://doi.org/10.1021/acs.jmedchem.5b00933.
- Rey M, Kramberg M, Hess P, Morrison K, Ernst R, Haag F, Weber E, Clozel M, Baumann M, Caroff E, et al. The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat. Pharmacol Res Perspect 2017;5(5):e00338. doi:https://doi.org/10.1002/prp2.338.
- Gachet C, Cazenave J-P, Ohlmann P, Bouloux C, Defreyn G, Driot F, Maffrand J-P. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochemical Pharmacology 1990;40(12):2683–2687. doi:https://doi.org/10.1016/0006-2952(90)90587-B.
- van Giezen JJJ, Sidaway J, Glaves P, Kirk I, Björkman J-A. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012;17(2):164–172. doi:https://doi.org/10.1177/1074248411410883.
- Kenakin TP. The Schild regression in the process of receptor classification. Can J Physiol Pharmacol 1982;60(3):249–265. doi:https://doi.org/10.1139/y82-036.
- Lazareno S, Birdsall NJM. Estimation of competitive antagonist affinity from functional inhibition curves using the Gaddum, Schild and Cheng-Prusoíf equations. British Journal of Pharmacology 1993;109(4):1110–1119. doi:https://doi.org/10.1111/j.1476-5381.1993.tb13737.x.
- Baurand A, Raboisson P, Freund M, Léon C, Cazenave J-P, Bourguignon J-J, Gachet C. Inhibition of platelet function by administration of MRS2179, a P2Y1 receptor antagonist. European Journal of Pharmacology 2001;412(3):213–221. doi:https://doi.org/10.1016/S0014-2999(01)00733-6.
- Kim Y-C, Lee J-S, Sak K, Marteau F, Mamedova L, Boeynaems J-M, Jacobson KA. Synthesis of pyridoxal phosphate derivatives with antagonist activity at the P2Y13 receptor. Biochemical Pharmacology 2005;70(2):266–274. doi:https://doi.org/10.1016/j.bcp.2005.04.021.
- North RA. Molecular Physiology of P2X Receptors. Physiological Reviews 2002;82(4):1013–1067. doi:https://doi.org/10.1152/physrev.00015.2002.
- Nelson DW, Gregg RJ, Kort ME, Perez-Medrano A, Voight EA, Wang Y, Grayson G, Namovic MT, Donnelly-Roberts DL, Niforatos W, et al. Structure−activity relationship studies on a series of novel, substituted 1-Benzyl-5-phenyltetrazole P2X7 Antagonists. J Med Chem 2006;49(12):3659–3666. doi:https://doi.org/10.1021/jm051202e.
- Van Giezen JJJ, Nilsson L, Berntsson P, Wissing B-M, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y12 independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. Journal of Thrombosis and Haemostasis 2009;7(9):1556–1565. doi:https://doi.org/10.1111/j.1538-7836.2009.03527.x.
- Hoffmann K, Lutz DA, Straßburger J, Baqi Y, Müller CE, von Kügelgen I. Competitive mode and site of interaction of ticagrelor at the human platelet P2Y 12 -receptor. Journal of Thrombosis and Haemostasis 2014;12(11):1898–1905. doi:https://doi.org/10.1111/jth.12719.
- Ufer M, Huynh C, van Lier JJ, Caroff E, Fischer H, Dingemanse J. Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects. Xenobiotica Published online August 7, 2019. 1–8. doi:https://doi.org/10.1080/00498254.2019.1646440.
- Juif P-E, Boehler M, Dobrow M, Ufer M, Dingemanse J. Clinical pharmacology of the reversible and potent P2Y 12 receptor antagonist ACT-246475 after single subcutaneous administration in healthy male subjects. The Journal of Clinical Pharmacology Published online August 8, 2018. doi:https://doi.org/10.1002/jcph.1296.
- Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux J-M, Hmissi A, Bernaud C, Ufer M, Moccetti T, et al. Subcutaneous selatogrel inhibits platelet aggregation in patients with acute myocardial infarction. Journal of the American College of Cardiology 2020;75(20):2588–2597. doi:https://doi.org/10.1016/j.jacc.2020.03.059.
- Schilling U, Dingemanse J, Ufer M. Pharmacokinetics and pharmacodynamics of approved and investigational P2Y12 receptor antagonists. Clin Pharmacokinet 2020;59(5):545–566. doi:https://doi.org/10.1007/s40262-020-00864-4.
- Baldoni D, Bruderer S, Krause A, Gutierrez M, Gueret P, Astruc B, Dingemanse J. A new reversible and potent P2Y12 receptor antagonist (ACT-246475): tolerability, pharmacokinetics, and pharmacodynamics in a first-in-man trial. Clin Drug Investig 2014;34(11):807–818. doi:https://doi.org/10.1007/s40261-014-0236-8.